Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan Set To Develop Biosimilar Botox In Deal With Revance

Executive Summary

Mylan's revenue was down due to issues in the North American market, but the company is looking forward to development of new products to balance out losses in the future, including a newly announced Botox biosimilar.


Related Content

Medical Aesthetics: Sales Rise For Popular Products, But Unmet Needs Remain
Merz Neurology Business Boosted By Xeomin Sialorrhea OK
Allergan Aesthetic Medicines Head Moatazedi Moves To Emerging Competitor Evolus
Biopharma Quarterly Dealmaking Statistics, Q1 2018
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
Mylan CEO Heather Bresch On How Mylan Is Different Than Teva
Revance's Long-Acting RT002 Will Have Slow-Moving Impact On Allergan
Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA
Surprise! Mylan's Copaxone Generic Sets Teva Up For A Struggle
Mylan Communications With CMS To Get Outside Review Under EpiPen Settlement


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts